HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boiron's Sales Grow Double-Digits In 2022 Despite Difficult End To Year

Executive Summary

French homeopathy specialist Boiron enjoyed a good 2022 after a few challenging years as a result of COVID-19 and France's decision to exclude homeopathic medicines from health insurance coverage.

You may also be interested in...



France's Boiron Reaping The Benefits Of Product Investments

Boiron's decision to diversify its portfolio away from non-proprietary homeopathic medicines is paying off, with sales for the opening nine months of 2022 up by a quarter, driven by new product launches in categories such as cosmetics and dietary supplements.

Boiron Partners With Galenica's Verfora In Switzerland

France's Boiron has granted Galenica's Verfora the rights to distribute in Switzerland its portfolio of over 800 products as it looks to turnaround its business and make cost savings following the collapse of homeopathy sales in its home market.

UK Rejects Blood Glucose Health Claim For White Mulberry Supplement

The UK Nutrition and Health Claims Committee has rejected the health claim “clinically proven in assisting healthy blood glucose levels” in the target population of type 2 diabetics for Ascarit’s white mulberry-based dietary supplement. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153292

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel